US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CITIUS ONCOLOGY INC

0.8101

+0.06018.01%

Pre-market: 0.7875-0.0226-2.79%04:00 EDT

Volume:134.13K

Turnover:102.58K

Market Cap:75.32M

PE:-1.64

High:0.8180

Open:0.7050

Low:0.7050

Close:0.7500

52wk High:2.25

52wk Low:0.4912

Shares:92.98M

Float Shares:18.20M

Volume Ratio:2.96

T/O Rate:0.74%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.4931

EPS(LYR):-0.3380

ROE:-126.58%

ROA:-29.12%

PB:1.87

PE(LYR):-2.40

Loading ...

Overview Company News Filings

Citius Oncology Inc expected to post a loss of 1 cent a share - Earnings Preview

Citius Pharma adds $0.9 share conversion option to $3.8 million Citius Oncology note

Citius Oncology issues new warrants for 25555556 shares after USD 11.5 million exercise

Citius Oncology enters up to $25 million senior secured loan facility with Avenue Capital Group

Citius Oncology, Inc. Secures up to $36.5 Million in Debt and Equity Capital to Accelerate Lymphir® Commercialization

THOMSON REUTERS

Citius Oncology announces initial shipment of LYMPHIR to Europe

Citius Oncology ships first international LYMPHIR order to Europe via named patient programs

Citius Oncology risks Nasdaq delisting after shares trade below $1 bid price rule

Citius Oncology provides commercial update on lymphir launch

Citius Oncology to Attend USCLC Annual Workshop to Discuss LYMPHIR™ in CTCL Treatment Sessions

Analysts Offer Insights on Healthcare Companies: Citius Oncology (CTOR) and Oruka Therapeutics (ORKA)

Citius Oncology’s Lymphir shows positive results in gynecologic cancers

Citius Oncology Inc - No Unexpected Safety Signals or Serious Immune-Related Adverse Events Observed

THOMSON REUTERS

Citius Oncology Announces Positive Topline Results From Investigator‑Initiated Phase 1 Study of Lymphir™ in Combination With Pembrolizumab in Relapsed or Refractory Gynecologic Cancers

THOMSON REUTERS

Citius Oncology Inc - Phase 1 Study Shows 24% Objective Response Rate, 48% Clinical Benefit Rate

THOMSON REUTERS

Analysts’ Top Healthcare Picks: Citius Oncology (CTOR), Karyopharm Therapeutics (KPTI)

BUZZ-Citius rises as lymphoma drug shows benefit in patients before CAR-T therapy

BRIEF-Citius Oncology Announces Preliminary Topline Phase 1 Data From Study Of Lymphir™ (E7777) Dosing Prior To Commercial Car‑T Therapy In High‑Risk Diffuse Large B‑Cell Lymphoma

Citius Oncology reports positive Phase 1 topline data for LYMPHIR before CAR-T in high-risk DLBCL

Citius Oncology Inc - Lymphir Well-Tolerated With No Dose-Limiting Toxicities Observed in Phase 1 Study

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/stock/CTOR/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"CTOR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTOR\",,,,,undefined,":{"symbol":"CTOR","market":"US","secType":"STK","nameCN":"CITIUS ONCOLOGY INC","latestPrice":0.8101,"timestamp":1787688000000,"preClose":0.75,"halted":0,"volume":134132,"hourTrading":{"tag":"盘前","latestPrice":0.7875,"preClose":0.8101,"latestTime":"04:00 EDT","volume":3,"amount":2.3625,"timestamp":1787731210523,"change":-0.0226,"changeRate":-0.027898,"amplitude":0},"delay":0,"changeRate":0.08013333333333339,"floatShares":18204800,"shares":92981204,"eps":-0.493118,"marketStatus":"Pre-Mkt","change":0.0601,"latestTime":"08-26 07:02:31 EDT","open":0.705,"high":0.818,"low":0.705,"amount":102577.5945452,"amplitude":0.150667,"askPrice":1.05,"askSize":200,"bidPrice":0.75,"bidSize":1070,"shortable":3,"etf":0,"ttmEps":-0.493118,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787751000000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":0.8101,"preHourTrading":{"tag":"盘前","latestPrice":0.7875,"preClose":0.8101,"latestTime":"04:00 EDT","volume":3,"amount":2.3625,"timestamp":1787731210523,"change":-0.0226,"changeRate":-0.027898,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":0.7601,"preClose":0.8101,"latestTime":"19:35 EDT","volume":517,"amount":393.5492,"timestamp":1787700929927,"change":-0.05,"changeRate":-0.061721,"amplitude":0.061721},"volumeRatio":2.955083207155116},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTOR\",,,,,undefined,":{"symbol":"CTOR","floatShares":18204800,"roa":"-29.12%","roe":"-126.58%","lyrEps":-0.337956,"volumeRatio":2.955083207155116,"shares":92981204,"dividePrice":0,"high":0.818,"amplitude":0.150667,"preClose":0.75,"low":0.705,"week52Low":0.4912,"pbRate":"1.87","psRate":"10.60","week52High":2.25,"institutionHeld":0,"latestPrice":0.8101,"committee":0.685039,"eps":-0.493118,"divideRate":0,"volume":134132,"delay":0,"ttmEps":-0.493118,"open":0.705,"prevYearClose":1,"prevWeekClose":0.7438,"prevMonthClose":0.5923,"prevQuarterClose":0.6501,"fiveDayClose":0.703,"twentyDayClose":0.5414,"sixtyDayClose":0.798},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CTOR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-14","symbol":"CTOR","fiscalQuarterEnding":"2026/06","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786680000000,"reportTimeType":"post","actualEps":-0.08},{"market":"US","date":"2026-05-15","symbol":"CTOR","fiscalQuarterEnding":"2026/03","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778817600000,"reportTimeType":"post","actualEps":-0.27},{"market":"US","date":"2026-02-13","symbol":"CTOR","fiscalQuarterEnding":"2025/12","expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1770958800000,"reportTimeType":"pre","actualEps":-0.06},{"market":"US","date":"2025-12-23","symbol":"CTOR","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1766466000000,"reportTimeType":"post","actualEps":-0.06},{"market":"US","date":"2025-08-12","symbol":"CTOR","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"post","actualEps":-0.08}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CTOR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CTOR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1758686400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CTOR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CTOR","date":"2026-08-25","current":-1.642812,"percent":0.880716,"low":-14.569058,"twenty":-5.385803,"median":-3.834182,"eighty":-2.306734,"high":-1.173027,"avg":-3.968078,"sd":1.954245,"marketCap":79319236},"quantilePoints":[{"date":"2024-08-23","current":-7.506449,"twenty":-8.175502,"median":-7.996,"eighty":-7.800179,"marketCap":131199450},{"date":"2024-08-30","current":-6.464428,"twenty":-8.028637,"median":-7.567643,"eighty":-6.639734,"marketCap":126208166},{"date":"2024-09-06","current":-6.847911,"twenty":-7.922567,"median":-7.149219,"eighty":-6.405992,"marketCap":133695091},{"date":"2024-09-13","current":-5.989639,"twenty":-7.726747,"median":-6.50095,"eighty":-6.274513,"marketCap":116938640},{"date":"2024-09-20","current":-6.099206,"twenty":-7.555404,"median":-6.464428,"eighty":-5.97503,"marketCap":119077761},{"date":"2024-09-27","current":-5.222673,"twenty":-7.472896,"median":-6.354861,"eighty":-5.953117,"marketCap":101964790},{"date":"2024-10-04","current":-4.309619,"twenty":-7.088957,"median":-6.190511,"eighty":-5.617113,"marketCap":84138777},{"date":"2024-10-11","current":-3.542653,"twenty":-6.749301,"median":-6.099206,"eighty":-5.018149,"marketCap":69164927},{"date":"2024-10-18","current":-3.944397,"twenty":-6.661648,"median":-5.953117,"eighty":-4.16353,"marketCap":77008372},{"date":"2024-10-25","current":-4.399098,"twenty":-6.559386,"median":-5.916595,"eighty":-4.331532,"marketCap":85885727},{"date":"2024-10-31","current":-4.419185,"twenty":-6.486341,"median":-5.66094,"eighty":-4.324228,"marketCap":86277899},{"date":"2024-11-08","current":-4.602892,"twenty":-6.464428,"median":-5.16789,"eighty":-4.287705,"marketCap":89864492},{"date":"2024-11-15","current":-3.904222,"twenty":-6.464428,"median":-4.930496,"eighty":-4.287705,"marketCap":76224028},{"date":"2024-11-22","current":-3.564201,"twenty":-6.420601,"median":-4.784407,"eighty":-3.944397,"marketCap":69585621},{"date":"2024-11-29","current":-3.356755,"twenty":-6.347557,"median":-4.693102,"eighty":-3.842134,"marketCap":65535551},{"date":"2024-12-06","current":-5.916595,"twenty":-6.296426,"median":-4.747885,"eighty":-3.776395,"marketCap":115512559},{"date":"2024-12-13","current":-3.907874,"twenty":-6.201468,"median":-4.620605,"eighty":-3.842134,"marketCap":76295332},{"date":"2024-12-20","current":-3.871352,"twenty":-6.164946,"median":-4.528752,"eighty":-3.842134,"marketCap":75582291},{"date":"2024-12-27","current":-3.50613,"twenty":-6.135728,"median":-4.435255,"eighty":-3.725263,"marketCap":68451887},{"date":"2025-01-03","current":-4.012144,"twenty":-6.10651,"median":-4.399098,"eighty":-3.717959,"marketCap":84851818},{"date":"2025-01-10","current":-3.992285,"twenty":-6.033466,"median":-4.399098,"eighty":-3.747177,"marketCap":84431834},{"date":"2025-01-17","current":-4.465946,"twenty":-5.967726,"median":-4.376046,"eighty":-3.723807,"marketCap":94449170},{"date":"2025-01-24","current":-4.296782,"twenty":-5.953117,"median":-4.35308,"eighty":-3.739872,"marketCap":90871550},{"date":"2025-01-31","current":-4.262949,"twenty":-5.953117,"median":-4.346141,"eighty":-3.761786,"marketCap":90156026},{"date":"2025-02-07","current":-4.026118,"twenty":-5.938508,"median":-4.309619,"eighty":-3.767526,"marketCap":85147358},{"date":"2025-02-14","current":-4.330615,"twenty":-5.916595,"median":-4.296782,"eighty":-3.799613,"marketCap":91587074},{"date":"2025-02-21","current":-3.72014,"twenty":-5.901986,"median":-4.296782,"eighty":-3.761786,"marketCap":85862882},{"date":"2025-02-28","current":-3.689139,"twenty":-5.807029,"median":-4.262949,"eighty":-3.720436,"marketCap":85147358},{"date":"2025-03-07","current":-3.162119,"twenty":-5.639027,"median":-4.229116,"eighty":-3.689139,"marketCap":72983450},{"date":"2025-03-14","current":-2.294087,"twenty":-5.507546,"median":-4.152992,"eighty":-3.653403,"marketCap":52948777},{"date":"2025-03-21","current":-1.891071,"twenty":-5.317631,"median":-4.127617,"eighty":-3.617985,"marketCap":43646965},{"date":"2025-03-28","current":-2.030577,"twenty":-5.251891,"median":-4.059951,"eighty":-3.565808,"marketCap":46866823},{"date":"2025-04-04","current":-2.191783,"twenty":-5.220193,"median":-4.053963,"eighty":-3.506186,"marketCap":50587548},{"date":"2025-04-11","current":-1.919282,"twenty":-5.198143,"median":-4.02178,"eighty":-3.38992,"marketCap":44298092},{"date":"2025-04-17","current":-2.002676,"twenty":-5.149629,"median":-4.014793,"eighty":-3.224122,"marketCap":46222851},{"date":"2025-04-25","current":-1.987175,"twenty":-5.113107,"median":-3.992285,"eighty":-3.104751,"marketCap":45865089},{"date":"2025-05-02","current":-2.759104,"twenty":-5.076585,"median":-3.944397,"eighty":-2.759104,"marketCap":63681637},{"date":"2025-05-09","current":-2.619599,"twenty":-4.930496,"median":-3.907874,"eighty":-2.693382,"marketCap":60461779},{"date":"2025-05-16","current":-2.437632,"twenty":-4.930496,"median":-3.890787,"eighty":-2.691522,"marketCap":63331031},{"date":"2025-05-23","current":-2.506208,"twenty":-4.784407,"median":-3.875146,"eighty":-2.619599,"marketCap":65112685},{"date":"2025-05-30","current":-2.451953,"twenty":-4.784407,"median":-3.871352,"eighty":-2.502848,"marketCap":63703103},{"date":"2025-06-06","current":-2.671453,"twenty":-4.755189,"median":-3.805483,"eighty":-2.487546,"marketCap":69405829},{"date":"2025-06-13","current":-4.04849,"twenty":-4.660231,"median":-3.776135,"eighty":-2.502848,"marketCap":105182030},{"date":"2025-06-20","current":-4.268817,"twenty":-4.617062,"median":-3.83483,"eighty":-2.506208,"marketCap":110906223},{"date":"2025-06-27","current":-9.639263,"twenty":-4.842843,"median":-3.873249,"eighty":-2.506208,"marketCap":250433407},{"date":"2025-07-03","current":-14.569058,"twenty":-5.098498,"median":-3.876214,"eighty":-2.511716,"marketCap":378512206},{"date":"2025-07-11","current":-8.950744,"twenty":-5.244587,"median":-3.890787,"eighty":-2.545647,"marketCap":232545306},{"date":"2025-07-18","current":-4.40652,"twenty":-5.303022,"median":-3.909331,"eighty":-2.598329,"marketCap":114483843},{"date":"2025-07-25","current":-5.370447,"twenty":-5.303022,"median":-3.944397,"eighty":-2.622079,"marketCap":139527183},{"date":"2025-08-01","current":-7.246465,"twenty":-5.617113,"median":-3.968341,"eighty":-2.631999,"marketCap":188267172},{"date":"2025-08-08","current":-6.066045,"twenty":-5.92757,"median":-3.993409,"eighty":-2.65122,"marketCap":157599217},{"date":"2025-08-15","current":-5.071831,"twenty":-5.92757,"median":-4.017441,"eighty":-2.668242,"marketCap":134797404},{"date":"2025-08-22","current":-4.806444,"twenty":-5.916595,"median":-4.026118,"eighty":-2.679481,"marketCap":127744051},{"date":"2025-08-29","current":-6.251327,"twenty":-5.92757,"median":-4.051227,"eighty":-2.692266,"marketCap":166145638},{"date":"2025-09-05","current":-5.514142,"twenty":-5.933303,"median":-4.056957,"eighty":-2.700326,"marketCap":146552992},{"date":"2025-09-12","current":-5.938837,"twenty":-5.933303,"median":-4.063335,"eighty":-2.734303,"marketCap":157840405},{"date":"2025-09-19","current":-5.498923,"twenty":-5.933303,"median":-4.134553,"eighty":-2.759104,"marketCap":146148523},{"date":"2025-09-26","current":-5.71888,"twenty":-5.924891,"median":-4.16145,"eighty":-2.75929,"marketCap":151994464},{"date":"2025-10-03","current":-5.907415,"twenty":-5.938047,"median":-4.221426,"eighty":-2.76177,"marketCap":157005270},{"date":"2025-10-10","current":-5.750303,"twenty":-5.938047,"median":-4.262949,"eighty":-2.769272,"marketCap":152829598},{"date":"2025-10-17","current":-5.624613,"twenty":-5.934887,"median":-4.265883,"eighty":-2.785269,"marketCap":149489061},{"date":"2025-10-24","current":-5.247544,"twenty":-5.933303,"median":-4.296782,"eighty":-2.845783,"marketCap":139467448},{"date":"2025-10-31","current":-5.436079,"twenty":-5.924891,"median":-4.3032,"eighty":-2.870708,"marketCap":144478254},{"date":"2025-11-07","current":-4.524828,"twenty":-5.916595,"median":-4.309619,"eighty":-2.884898,"marketCap":120259356},{"date":"2025-11-14","current":-4.179182,"twenty":-5.914759,"median":-4.309619,"eighty":-2.896465,"marketCap":111072877},{"date":"2025-11-21","current":-3.550733,"twenty":-5.907415,"median":-4.304871,"eighty":-2.952238,"marketCap":94370189},{"date":"2025-11-28","current":-4.304871,"twenty":-5.907415,"median":-4.296782,"eighty":-3.104751,"marketCap":114413415},{"date":"2025-12-05","current":-3.487889,"twenty":-5.875992,"median":-4.296782,"eighty":-3.112056,"marketCap":92699920},{"date":"2025-12-12","current":-3.550733,"twenty":-5.86799,"median":-4.273096,"eighty":-3.162119,"marketCap":94370189},{"date":"2025-12-19","current":-3.582156,"twenty":-5.84457,"median":-4.262949,"eighty":-3.19281,"marketCap":95205323},{"date":"2025-12-26","current":-3.92117,"twenty":-5.843755,"median":-4.262949,"eighty":-3.21786,"marketCap":97093533},{"date":"2026-01-02","current":-3.424602,"twenty":-5.82283,"median":-4.235196,"eighty":-3.269261,"marketCap":84797846},{"date":"2026-01-09","current":-3.869801,"twenty":-5.792641,"median":-4.210604,"eighty":-3.333795,"marketCap":95821565},{"date":"2026-01-16","current":-3.698571,"twenty":-5.781725,"median":-4.16249,"eighty":-3.356755,"marketCap":91581673},{"date":"2026-01-23","current":-3.835555,"twenty":-5.769156,"median":-4.143012,"eighty":-3.358933,"marketCap":94973587},{"date":"2026-01-30","current":-3.921541,"twenty":-5.737734,"median":-4.109523,"eighty":-3.368971,"marketCap":97102724},{"date":"2026-02-06","current":-3.957191,"twenty":-5.706311,"median":-4.080473,"eighty":-3.382482,"marketCap":97985476},{"date":"2026-02-13","current":-4.206744,"twenty":-5.687458,"median":-4.063335,"eighty":-3.402348,"marketCap":104164740},{"date":"2026-02-20","current":-4.519036,"twenty":-5.682154,"median":-4.084915,"eighty":-3.42469,"marketCap":106812996},{"date":"2026-02-27","current":-4.070867,"twenty":-5.656708,"median":-4.104658,"eighty":-3.426652,"marketCap":96219972},{"date":"2026-03-06","current":-3.996173,"twenty":-5.636748,"median":-4.084915,"eighty":-3.433086,"marketCap":94454468},{"date":"2026-03-13","current":-3.398614,"twenty":-5.624613,"median":-4.070867,"eighty":-3.433086,"marketCap":80330435},{"date":"2026-03-20","current":-2.579959,"twenty":-5.624613,"median":-4.059951,"eighty":-3.389732,"marketCap":60980510},{"date":"2026-03-27","current":-2.020495,"twenty":-5.620211,"median":-4.053963,"eighty":-3.356755,"marketCap":47756885},{"date":"2026-04-02","current":-2.420485,"twenty":-5.602604,"median":-4.04849,"eighty":-3.19281,"marketCap":57211159},{"date":"2026-04-10","current":-2.464929,"twenty":-5.593191,"median":-4.028492,"eighty":-3.034103,"marketCap":58261634},{"date":"2026-04-17","current":-3.007213,"twenty":-5.593191,"median":-4.027305,"eighty":-2.91411,"marketCap":71079194},{"date":"2026-04-24","current":-3.65183,"twenty":-5.573117,"median":-4.02207,"eighty":-3.007213,"marketCap":86315494},{"date":"2026-05-01","current":-3.286198,"twenty":-5.551373,"median":-4.014793,"eighty":-3.009828,"marketCap":77673351},{"date":"2026-05-08","current":-3.364628,"twenty":-5.543629,"median":-3.993409,"eighty":-3.034103,"marketCap":79527131},{"date":"2026-05-15","current":-3.676105,"twenty":-5.530346,"median":-3.975555,"eighty":-3.099835,"marketCap":86889283},{"date":"2026-05-22","current":-1.721465,"twenty":-5.514142,"median":-3.957191,"eighty":-2.91411,"marketCap":73180144},{"date":"2026-05-29","current":-1.674951,"twenty":-5.514142,"median":-3.944397,"eighty":-2.880009,"marketCap":71202779},{"date":"2026-06-05","current":-1.652731,"twenty":-5.501967,"median":-3.944397,"eighty":-2.770947,"marketCap":70258234},{"date":"2026-06-12","current":-1.438015,"twenty":-5.498923,"median":-3.938293,"eighty":-2.752904,"marketCap":61130578},{"date":"2026-06-18","current":-1.370943,"twenty":-5.498923,"median":-3.927802,"eighty":-2.683494,"marketCap":58279289},{"date":"2026-06-26","current":-1.443591,"twenty":-5.48007,"median":-3.921541,"eighty":-2.625689,"marketCap":61367594},{"date":"2026-07-02","current":-1.540487,"twenty":-5.454932,"median":-3.92117,"eighty":-2.581635,"marketCap":65486661},{"date":"2026-07-10","current":-1.57767,"twenty":-5.436079,"median":-3.907874,"eighty":-2.528121,"marketCap":67067342},{"date":"2026-07-17","current":-1.491711,"twenty":-5.431919,"median":-3.890787,"eighty":-2.506208,"marketCap":63413181},{"date":"2026-07-24","current":-1.264673,"twenty":-5.422175,"median":-3.877282,"eighty":-2.478998,"marketCap":53761732},{"date":"2026-07-31","current":-1.255049,"twenty":-5.414466,"median":-3.875146,"eighty":-2.461623,"marketCap":53352614},{"date":"2026-08-07","current":-1.662317,"twenty":-5.404656,"median":-3.870576,"eighty":-2.451127,"marketCap":70665715},{"date":"2026-08-14","current":-1.808426,"twenty":-5.404656,"median":-3.869801,"eighty":-2.413051,"marketCap":76876859},{"date":"2026-08-21","current":-1.532251,"twenty":-5.398372,"median":-3.835192,"eighty":-2.327137,"marketCap":70582031},{"date":"2026-08-25","current":-1.721926,"twenty":-5.385803,"median":-3.834182,"eighty":-2.306734,"marketCap":79319236}],"updateTime":1787736674733},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CTOR\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2634636460","title":"Citius Oncology Inc  expected to post a loss of 1 cent a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2634636460","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634636460?lang=en_us&edition=fundamental","pubTime":"2026-05-09 05:52","pubTimestamp":1778277126,"startTime":"0","endTime":"0","summary":"Citius Oncology Inc  expected to post a loss of 1cent a share - Earnings Preview Citius Oncology Inc CTOR.OQ CTOR.O is expected to  show a rise in quarterly revenue when it reports  results on May 12 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L2QD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CTXR","BK4139","CTOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634446257","title":"Citius Pharma adds $0.9 share conversion option to $3.8 million Citius Oncology note","url":"https://stock-news.laohu8.com/highlight/detail?id=2634446257","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634446257?lang=en_us&edition=fundamental","pubTime":"2026-05-09 04:32","pubTimestamp":1778272344,"startTime":"0","endTime":"0","summary":"Citius Pharmaceuticals amended promissory note issued by Citius Oncology to align payment terms with subsidiary debt facility subordination.Unpaid principal of USD 3.8 million now due 91 days after Citius Oncology fully repays senior debt and terminates related loan and security agreement.Prior maturity triggers tied to financings were removed; cash prepayment barred before new maturity.Amendment adds optional conversion, subject to Citius Oncology approval, into common stock at USD 0.9 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securitie","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDL77MGWQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTXR","BK4139","BK4007","CTOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633975228","title":"Citius Oncology issues new warrants for 25555556 shares after USD 11.5 million exercise","url":"https://stock-news.laohu8.com/highlight/detail?id=2633975228","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633975228?lang=en_us&edition=fundamental","pubTime":"2026-05-06 08:09","pubTimestamp":1778026188,"startTime":"0","endTime":"0","summary":"Citius Oncology set immediate exercise of outstanding warrants for 12,777,778 shares at USD 0.9 per share, targeting about USD 11.5 million in gross proceeds; closing expected May 6, 2026.New unregistered warrants to buy 25,555,556 shares to be issued as consideration; exercise price USD 0.9; expiry five years after later of stockholder approval or effectiveness of resale registration statement.Company to issue Avenue warrants for 11,111,111 shares at USD 0.9 in connection with a senior credit facility; additional warrant coverage tied to any future tranche funding.Registration statement to be filed covering resale of shares underlying new warrants.Existing December 2025 warrants for 15,697,024 shares to be amended at closing to cut exercise price to USD 0.9 from USD 1.09; exercisable after stockholder approval.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL6qwFdV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CTOR","CTXR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633975192","title":"Citius Oncology enters up to $25 million senior secured loan facility with Avenue Capital Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2633975192","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633975192?lang=en_us&edition=fundamental","pubTime":"2026-05-06 08:01","pubTimestamp":1778025714,"startTime":"0","endTime":"0","summary":"Citius Oncology entered senior secured term loan credit facility with Avenue Venture Opportunities Fund II, providing up to USD 25 million to support LYMPHIR commercialization.Facility includes USD 10 million initial tranche funded at closing, with up to USD 15 million in additional tranches tied to revenue milestones and liquidity conditions.Avenue received warrants for 11,111,111 shares at USD 0.9 per share, with additional warrant coverage tied to any future tranche funding.Separate warrant exercise agreement with single institutional investor expected to deliver about USD 11.5 million in gross proceeds at USD 0.9 per share, alongside issuance of new unregistered warrants for 25,555,556 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL77bQQ0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTOR","BK4139","BK4007","CTXR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633938975","title":"Citius Oncology, Inc. Secures up to $36.5 Million in Debt and Equity Capital to Accelerate Lymphir® Commercialization","url":"https://stock-news.laohu8.com/highlight/detail?id=2633938975","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633938975?lang=en_us&edition=fundamental","pubTime":"2026-05-06 08:00","pubTimestamp":1778025600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nTUA9STMQJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CTOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631654542","title":"Citius Oncology announces initial shipment of LYMPHIR to Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2631654542","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631654542?lang=en_us&edition=fundamental","pubTime":"2026-04-29 22:53","pubTimestamp":1777474438,"startTime":"0","endTime":"0","summary":"Citius Oncology (CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, (CTXR), announced the initial shipment of LYMPHIR to Europe through ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/citius-oncology-announces-initial-shipment-of-lymphir-to-europe-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/citius-oncology-announces-initial-shipment-of-lymphir-to-europe-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CTXR","BK4139","BK4007","CTOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631566519","title":"Citius Oncology ships first international LYMPHIR order to Europe via named patient programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2631566519","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631566519?lang=en_us&edition=fundamental","pubTime":"2026-04-29 20:09","pubTimestamp":1777464596,"startTime":"0","endTime":"0","summary":"Citius Oncology shipped first international order of LYMPHIR to Europe, expanding access beyond United States.Distribution will run through regional partners via Named Patient Programs under local country rules.LYMPHIR lacks European Medicines Agency marketing authorization, limiting availability to Named Patient Programs.U.S. rollout began in December 2025 following FDA clearance in August 2024 for adult Stage I-III relapsed or refractory CTCL after at least one prior systemic therapy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Oncology Inc. published the original content used to generate this news brief on April 29, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL8rcWJQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTXR","BK4007","CTOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631531306","title":"Citius Oncology risks Nasdaq delisting after shares trade below $1 bid price rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2631531306","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631531306?lang=en_us&edition=fundamental","pubTime":"2026-04-29 05:13","pubTimestamp":1777410801,"startTime":"0","endTime":"0","summary":"Nasdaq notified Citius Oncology on April 22, 2026 that CTOR failed to meet $1 minimum bid price rule for 30 consecutive business days.Stock has until Oct. 19, 2026 to regain compliance by closing at or above $1 for 10 consecutive business days.Failure to cure by deadline could trigger delisting notice, with option to seek a second 180-day cure period if other listing standards are met.Company is evaluating steps to restore compliance, including potential reverse stock split.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nNDLGHwpY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623582004","title":"Citius Oncology provides commercial update on lymphir launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2623582004","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623582004?lang=en_us&edition=fundamental","pubTime":"2026-03-31 21:40","pubTimestamp":1774964430,"startTime":"0","endTime":"0","summary":"Citius Oncology (CTOR)provided a commercial update on the U.S. launch of lymphir for the treatment of cutaneous T-cell lymphoma, highlighting conti...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/citius-oncology-provides-commercial-update-on-lymphir-launch-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/citius-oncology-provides-commercial-update-on-lymphir-launch-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CTOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621646610","title":"Citius Oncology to Attend USCLC Annual Workshop to Discuss LYMPHIR™ in CTCL Treatment Sessions","url":"https://stock-news.laohu8.com/highlight/detail?id=2621646610","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621646610?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:02","pubTimestamp":1774353774,"startTime":"0","endTime":"0","summary":"Citius Oncology plans to attend the USCLC Annual Workshop 2026 on March 26, 2026, in Denver, Colorado.The company’s commercial and medical affairs teams are scheduled to take part in discussions on clinical experience with LYMPHIR for cutaneous T-cell lymphoma.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Oncology Inc. published the original content used to generate this news brief via PR Newswire  on March 24, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL6lh8pz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTOR","BK4007","CTXR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619197263","title":"Analysts Offer Insights on Healthcare Companies: Citius Oncology (CTOR) and Oruka Therapeutics (ORKA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2619197263","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619197263?lang=en_us&edition=fundamental","pubTime":"2026-03-13 20:50","pubTimestamp":1773406204,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Citius Oncology (CTOR – Research Report) and Oruka T...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-citius-oncology-ctor-and-oruka-therapeutics-orka-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-citius-oncology-ctor-and-oruka-therapeutics-orka-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","BK4585","HCSG","BK4588","LU0029874061.USD","ORKA","XBI","CTOR","LU0128526141.USD","BK4581","BK4137","BK4139","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618953606","title":"Citius Oncology’s Lymphir shows positive results in gynecologic cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2618953606","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618953606?lang=en_us&edition=fundamental","pubTime":"2026-03-10 20:58","pubTimestamp":1773147481,"startTime":"0","endTime":"0","summary":"Citius Oncology (CTOR)announced positive topline results from a completed investigator-initiated Phase1 clinical trial evaluating the direct T-regu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/citius-oncologys-lymphir-shows-positive-results-in-gynecologic-cancers-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/citius-oncologys-lymphir-shows-positive-results-in-gynecologic-cancers-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CTOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618958292","title":"Citius Oncology Inc - No Unexpected Safety Signals or Serious Immune-Related Adverse Events Observed","url":"https://stock-news.laohu8.com/highlight/detail?id=2618958292","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618958292?lang=en_us&edition=fundamental","pubTime":"2026-03-10 20:47","pubTimestamp":1773146820,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nTUA3F4VYN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CTOR","CTXR","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618582949","title":"Citius Oncology Announces Positive Topline Results From Investigator‑Initiated Phase 1 Study of Lymphir™ in Combination With Pembrolizumab in Relapsed or Refractory Gynecologic Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2618582949","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618582949?lang=en_us&edition=fundamental","pubTime":"2026-03-10 20:47","pubTimestamp":1773146820,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nTUA3F4VYN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CTOR","CTXR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618095829","title":"Citius Oncology Inc - Phase 1 Study Shows 24% Objective Response Rate, 48% Clinical Benefit Rate","url":"https://stock-news.laohu8.com/highlight/detail?id=2618095829","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618095829?lang=en_us&edition=fundamental","pubTime":"2026-03-10 20:47","pubTimestamp":1773146820,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nTUA3F4VYN:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CTXR","CTOR","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617668219","title":"Analysts’ Top Healthcare Picks: Citius Oncology (CTOR), Karyopharm Therapeutics (KPTI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2617668219","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617668219?lang=en_us&edition=fundamental","pubTime":"2026-03-08 01:50","pubTimestamp":1772905843,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Citius Oncology (CTOR – Research Report) and Karyoph...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-citius-oncology-ctor-karyopharm-therapeutics-kpti-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-citius-oncology-ctor-karyopharm-therapeutics-kpti-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","BK4588","LU0029874061.USD","CTOR","BK4137","KPTI","XLV","BK4581","LABU","XBI","BK4585","BK4139","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616849551","title":"BUZZ-Citius rises as lymphoma drug shows benefit in patients before CAR-T therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2616849551","media":"Reuters","labels":["shareholding","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616849551?lang=en_us&edition=fundamental","pubTime":"2026-03-04 23:08","pubTimestamp":1772636897,"startTime":"0","endTime":"0","summary":"BUZZ-Citius rises as lymphoma drug shows benefit in patients before CAR-T therapy** Shares of drugmaker Citius Oncology CTOR.O rise 1.89% to $1.08 ** Co says early data shows its drug Lymphir may benefit patients with aggressive lymphoma, when administered before CAR-T therapy** High-risk diffuse large B-cell lymphoma is a fastgrowing blood cancer** Co says 86% of 14 patients showed improvement after a single Lymphir dose administered before CAR-T, with over half reaching complete remission** Mild side effects were reported; all patients were able to proceed with CAR-T, co says** Lymphir was approved in 2024 to treat certain adult patients with a group of rare blood cancers that affects the skin** Shares down ~13% in 2025  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nL4N3ZS1F4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","CTXR","CTOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616556435","title":"BRIEF-Citius Oncology Announces Preliminary Topline Phase 1 Data From Study Of Lymphir™ (E7777) Dosing Prior To Commercial Car‑T Therapy In High‑Risk Diffuse Large B‑Cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2616556435","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616556435?lang=en_us&edition=fundamental","pubTime":"2026-03-04 22:20","pubTimestamp":1772634031,"startTime":"0","endTime":"0","summary":"BRIEF-Citius Oncology Announces Preliminary Topline Phase 1 Data From Study Of Lymphir (E7777) Dosing Prior To Commercial CarT Therapy In HighRisk Diffuse Large BCell LymphomaMarch 4 (Reuters) - Citiu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nTUABRQ24D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616556500","title":"Citius Oncology reports positive Phase 1 topline data for LYMPHIR before CAR-T in high-risk DLBCL","url":"https://stock-news.laohu8.com/highlight/detail?id=2616556500","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616556500?lang=en_us&edition=fundamental","pubTime":"2026-03-04 22:15","pubTimestamp":1772633741,"startTime":"0","endTime":"0","summary":"Citius Oncology Inc. reported preliminary topline safety and efficacy data from an investigator-initiated Phase 1 trial evaluating LYMPHIR  administered prior to commercial CD19-directed CAR-T therapy in 14 patients with high-risk relapsed or refractory diffuse large B-cell lymphoma. The company said the overall response rate at one month was 86%, including 57% complete responses and 29% partial responses, with no dose-limiting toxicities observed up to 9 g/kg. The results were presented at the 2026 ASTCT and CIBMTR Tandem Meetings.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Oncology Inc. published the original content used to generate this news brief via PR Newswire  on March 04, 2026, and is solely responsible for the info","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDL5r5HPN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTXR","BK4007","CTOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616565165","title":"Citius Oncology Inc - Lymphir Well-Tolerated With No Dose-Limiting Toxicities Observed in Phase 1 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2616565165","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616565165?lang=en_us&edition=fundamental","pubTime":"2026-03-04 22:15","pubTimestamp":1772633701,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nTUABRQ24D:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CTOR"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":41,"code":"91000000","status":"200"}]}}